利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.036 秒)

    COMPOUNDS WITH SUPER-ASPIRIN EFFECTS
    1.
    发明申请
    COMPOUNDS WITH SUPER-ASPIRIN EFFECTS 审中-公开
    具有超级阿司匹林效应的化合物

    公开(公告)号：US20140024681A1

    公开(公告)日：2014-01-23

    申请号：US13980533

    申请日：2012-01-20

    申请人： John Francis Gilmer ,  Mark Ledwidge ,  Pat O'lynn ,  Shona Harmon ,  Mark Radomski ,  Carlos Medina Martin

    发明人： John Francis Gilmer ,  Mark Ledwidge ,  Pat O'lynn ,  Shona Harmon ,  Mark Radomski ,  Carlos Medina Martin

    IPC分类号： C07D493/04

    CPC分类号： C07D493/04

    摘要： A compound having the structural formula (I) and pharmaceutically acceptable salt and/or hydrates thereof, (I) wherein Y is an arylester or an C1-C8 alkylaryl ester, selected from the group consisting of: benzene, toluene, xylene, benzoic acid, benzoate, nicotinate, isonicotinate and halobenzene, which can be unsubstituted or substituted with at least one nitric oxide releasing group; and/or at least one of hydroxide, —Cl, —Br, a C1-C8 alkyl, benzyl, a C1-C8 alkoxy, benzyloxy, —NHC(O)R, —NH2, —NO2—ONO2, —(CH2)nONO2, —OC(O)[(CH2)n]cyclicONO2, —OCOArONO2, —OCOAr(CH2)nONO2 or a C1-C5 haloalkyl ester, wherein R is a C1-C8 alkyl or a C1-C8 alkoxy group, n=1-8 and m=3-10, to produce a super-aspirin effect.

    摘要翻译： 具有结构式（I）的化合物及其药学上可接受的盐和/或其水合物，（I）其中Y是芳基酯或C1-C8烷基芳基酯，选自：苯，甲苯，二甲苯，苯甲酸 苯甲酸盐，烟酸盐，异烟酸盐和卤代苯，其可以是未取代的或被至少一个一氧化氮释放基团取代; 和/或氢氧化物，-Cl，-Br，C1-C8烷基，苄基，C1-C8烷氧基，苄氧基，-NHC（O）R，-NH2，-NO2-ONO2， - （CH2） NONO 2，-OC（O）[（CH 2）n]环氧基，-OCOOOR 2，-OCOAr（CH 2）nONO 2或C 1 -C 5卤代烷基酯，其中R是C 1 -C 8烷基或C 1 -C 8烷氧基，n = 1-8和m = 3-10，以产生超阿司匹林效应。

    COMPOUNDS FOR TREATMENT OF HEART FAILURE
    2.
    发明申请
    COMPOUNDS FOR TREATMENT OF HEART FAILURE 有权
    用于治疗心脏衰竭的化合物

    公开(公告)号：US20130338118A1

    公开(公告)日：2013-12-19

    申请号：US13992663

    申请日：2011-12-08

    申请人： John Gilmer ,  Mark Ledwidge ,  Ken McDonald ,  Pat O'Flynn

    发明人： John Gilmer ,  Mark Ledwidge ,  Ken McDonald ,  Pat O'Flynn

    IPC分类号： A61K47/48 ,  A61K45/06

    CPC分类号： A61K47/481 ,  A61K31/00 ,  A61K31/21 ,  A61K31/4458 ,  A61K31/4462 ,  A61K31/4465 ,  A61K31/65 ,  A61K45/06 ,  A61K47/55 ,  C07C237/26 ,  A61K2300/00

    摘要： A combination of: a first tetracycline (TC) component; and a second component capable of releasing nitric oxide (NO) or a nitrate capable of mimicking NO effects in vivo (NO mimetic). The combinations of the invention advantageously act as more effective MMP modulators with selective reductions in circulating MMP-9 levels in-vivo and inhibitory effects on MMP-2 and MMP-9 levels in-vitro. The combinations of the invention also advantageously act as modulators of inflammation mediators. The co-existence of abnormalities of MMP enzymes and inflammation in many diseases make these characteristics advantageous. Therefore, the various combinations of the invention find utility in medical applications where MMPs and/or inflammation is implicated.

    摘要翻译： 一种组合：第一种四环素（TC）组分; 以及能够释放一氧化氮（NO）或能够体内模拟NO作用的硝酸盐（NO模拟物）的第二成分。 本发明的组合有利地作为更有效的MMP调节剂，其具有在体内循环中MMP-9水平的选择性降低和对体外MMP-2和MMP-9水平的抑制作用。 本发明的组合也有利地用作炎症介质的调节剂。 许多疾病中MMP酶异常和炎症的共存使得这些特征是有利的。 因此，本发明的各种组合可用于涉及MMP和/或炎症的医学应用中。

    EVALUATION OF A SUBJECT'S WEIGHT
    4.
    发明申请
    EVALUATION OF A SUBJECT'S WEIGHT 审中-公开
    评估主体的重量

    公开(公告)号：US20120330683A1

    公开(公告)日：2012-12-27

    申请号：US13581452

    申请日：2011-02-25

    申请人： Mark Ledwidge ,  Kenneth McDonald

    发明人： Mark Ledwidge ,  Kenneth McDonald

    IPC分类号： G06Q50/24

    CPC分类号： A61B5/0002 ,  G01G19/50 ,  G06F19/325 ,  G16H15/00 ,  G16H50/20

    摘要： A method and system for evaluating a subject's weight calculates a moving average of the weight of the subject based on several consecutive weight measurements e.g. on consecutive days. Rather than looking for absolute weight gains of e.g. 2 kg in 48 hours, as with currently accepted guidelines, each new measurement is compared with the calculated moving average, and a first form of alert is generated if the new measurement differs from the calculated moving average by more than a with expected range threshold amount such as by one standard deviation. If the first form of alert is generated consecutively on a predetermined number of successive iterations, a second form of alert is generated different from the first form of alert. The system and method does not assume a stable underlying patient weight, and absolute weight gains over e.g. a 48 hour period are not used as in currently accepted guidelines, which results in earlier alerting of clinical deteriorations and greatly increased sensitivity relative to published guideline methods.

    摘要翻译： 用于评估受试者体重的方法和系统基于几个连续的体重测量来计算受试者的体重的移动平均值。 连续几天 而不是寻找例如绝对体重增加。 在48小时内按照当前接受的指导方针2公斤，将每个新的测量值与计算的移动平均值进行比较，如果新测量值与计算的移动平均值不同，则生成第一种形式的警报，超过预期范围阈值量 例如一个标准偏差。 如果在预定数量的连续迭代上连续生成第一形式的警报，则产生与第一警报形式不同的第二形式的警报。 系统和方法不承担稳定的潜在患者体重，并且绝对体重增加超过例如体重。 目前接受的指南中没有使用48小时的时间段，这导致临床恶化的早期报警和相对于公布的指南方法的敏感性大大增加。

    BIOMARKERS OF CARDIOVASCULAR DISEASE INCLUDING LRG
    5.
    发明申请
    BIOMARKERS OF CARDIOVASCULAR DISEASE INCLUDING LRG 审中-公开
    包括LRG的心血管病的生物标志物

    公开(公告)号：US20130084276A1

    公开(公告)日：2013-04-04

    申请号：US13575276

    申请日：2011-01-26

    申请人： Chris Watson ,  Mark Ledwidge ,  Kenneth McDonald ,  John Baugh

    发明人： Chris Watson ,  Mark Ledwidge ,  Kenneth McDonald ,  John Baugh

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2500/04 ,  G01N2800/325

    摘要： The invention relates to differentially expressed disease - associated proteins that have potential to identify patients with cardiovascular disease including ventricular dysfunction and heart failure and the potential to predict heart failure in patients. In particular, the invention relates to the use of a panel of biomarkers in the diagnostic and prognostic evaluation of cardiovascular patients. One of the markers is Leucine-rich alpha-2-glycoprotein (LRG).

    摘要翻译： 本发明涉及差异表达的疾病相关蛋白，其具有鉴定心血管疾病患者的潜力，包括心室功能障碍和心力衰竭以及预测患者心力衰竭的可能性。 特别地，本发明涉及一组生物标志物在心血管病患者的诊断和预后评价中的应用。 其中一个标记是富含亮氨酸的α-2-糖蛋白（LRG）。

    Compounds for treatment of heart failure
    6.
    发明授权
    Compounds for treatment of heart failure 有权
    用于治疗心力衰竭的化合物

    公开(公告)号：US09566342B2

    公开(公告)日：2017-02-14

    申请号：US13992663

    申请日：2011-12-08

    申请人： John Gilmer ,  Mark Ledwidge ,  Ken McDonald ,  Pat O'Flynn

    发明人： John Gilmer ,  Mark Ledwidge ,  Ken McDonald ,  Pat O'Flynn

    IPC分类号： A61K45/06 ,  A61K47/48 ,  A61K31/00 ,  A61K31/21 ,  A61K31/4458 ,  A61K31/4462 ,  A61K31/4465 ,  A61K31/65 ,  C07C237/26

    CPC分类号： A61K47/481 ,  A61K31/00 ,  A61K31/21 ,  A61K31/4458 ,  A61K31/4462 ,  A61K31/4465 ,  A61K31/65 ,  A61K45/06 ,  A61K47/55 ,  C07C237/26 ,  A61K2300/00

    摘要： A combination of: a first tetracycline (TC) component; and a second component capable of releasing nitric oxide (NO) or a nitrate capable of mimicking NO effects in vivo (NO mimetic). The combinations of the invention advantageously act as more effective MMP modulators with selective reductions in circulating MMP-9 levels in-vivo and inhibitory effects on MMP-2 and MMP-9 levels in-vitro. The combinations of the invention also advantageously act as modulators of inflammation mediators. The co-existence of abnormalities of MMP enzymes and inflammation in many diseases make these characteristics advantageous. Therefore, the various combinations of the invention find utility in medical applications where MMPs and/or inflammation is implicated.

    摘要翻译： 一种组合：第一种四环素（TC）组分; 以及能够释放一氧化氮（NO）或能够体内模拟NO作用的硝酸盐（NO模拟物）的第二成分。 本发明的组合有利地作为更有效的MMP调节剂，其具有在体内循环中MMP-9水平的选择性降低和对体外MMP-2和MMP-9水平的抑制作用。 本发明的组合也有利地用作炎症介质的调节剂。 许多疾病中MMP酶异常和炎症的共存使得这些特征是有利的。 因此，本发明的各种组合可用于涉及MMP和/或炎症的医学应用中。